[{"address1": "7171 Rue Frederick Banting", "city": "Saint-Laurent", "state": "QC", "zip": "H4S 1Z9", "country": "Canada", "phone": "514 332 4888", "website": "https://www.engene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Gu\u00e9rin. The company was founded in 2023 and is based in Saint-Laurent, Canada.", "fullTimeEmployees": 31, "maxAge": 86400, "priceHint": 2, "previousClose": 8.71, "open": 8.49, "dayLow": 8.49, "dayHigh": 9.71, "regularMarketPreviousClose": 8.71, "regularMarketOpen": 8.49, "regularMarketDayLow": 8.49, "regularMarketDayHigh": 9.71, "beta": -0.641, "forwardPE": -5.6962023, "volume": 25297, "regularMarketVolume": 25297, "averageVolume": 83512, "averageVolume10days": 188540, "averageDailyVolume10Day": 188540, "bid": 8.69, "bidSize": 200, "marketCap": 397495808, "fiftyTwoWeekLow": 6.69, "fiftyTwoWeekHigh": 47.17, "fiftyDayAverage": 12.6811, "twoHundredDayAverage": 11.818365, "currency": "USD", "enterpriseValue": 157369424, "floatShares": 14849988, "sharesOutstanding": 44166200, "sharesShort": 19755, "sharesShortPriorMonth": 72740, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.13344, "heldPercentInstitutions": 0.8201, "shortRatio": 0.21, "shortPercentOfFloat": 0.00059999997, "impliedSharesOutstanding": 44166200, "lastFiscalYearEnd": 1698710400, "nextFiscalYearEnd": 1730332800, "mostRecentQuarter": 1714435200, "netIncomeToCommon": -115345000, "forwardEps": -1.58, "enterpriseToEbitda": -3.535, "52WeekChange": -0.160056, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ENGN", "underlyingSymbol": "ENGN", "shortName": "enGene Holdings Inc.", "longName": "enGene Holdings Inc.", "firstTradeDateEpochUtc": 1643725800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f9f4e2ed-4011-3f93-916a-f8a188a8b358", "messageBoardId": "finmb_9516520", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.0, "targetHighPrice": 40.0, "targetLowPrice": 27.0, "targetMeanPrice": 33.0, "targetMedianPrice": 34.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 264810000, "totalCashPerShare": 5.996, "ebitda": -44523000, "totalDebt": 24684000, "quickRatio": 42.233, "currentRatio": 42.802, "debtToEquity": 10.159, "operatingCashflow": -35608000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]